Calidi Biotherapeutics (CLDI) Receivables - Net (2022 - 2023)
Calidi Biotherapeutics (CLDI) posted Receivables - Net of $870.0 for Q2 2023, little changed on a QoQ basis from $870.0 in Q4 2022.
Powered by 
Analysis
Calidi Biotherapeutics (CLDI) Receivables - Net (2022 - 2023) Analysis & Trends
Calidi Biotherapeutics has reported Receivables - Net for 2 years, with the latest figure at $870.0 in Q2 2023.
- On a quarterly basis, Receivables - Net changed N/A year-over-year to $870.0 in Q2 2023; TTM through Jun 2023 was $870.0, a N/A change from a year earlier, with the FY2022 full-year figure at $870.0, changed N/A from the prior year.
- Receivables - Net was $870.0 for Q2 2023 at Calidi Biotherapeutics, roughly flat from $870.0 in the prior quarter.
- The five-year high for Receivables - Net was $870.0 in Q4 2022, with the low at $870.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.56 Bn | 2.60 Bn | 251.50 Mn |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.19 Bn | 1.39 Bn | 251.87 Mn |
| 9 | Vericel | 1.96 Bn | 1.79 Bn | 56.40 Mn |
| 10 | Calidi Biotherapeutics | 1.87 Mn | -2.23 Mn | - |